文献速递肿瘤 PET/CT

直肠癌中的[18F]氟米索硝唑PET显像

[18F]Fluoromisonidazole PET in rectal cancer.
PubMed 文献 · EJNMMI Res · 2017-09-20

该试点研究纳入经活检证实的直肠腺癌患者,在新辅助放化疗前及第2周(8-10次分割后)行[18F]FMISO PET扫描,分析肿瘤-肌肉及肿瘤-血液SUVmax和动态参数。11例中5例为良好反应者、6例为不良反应者;除灌注变化外,其他PET参数变化与临床结局未见明确趋势。作者指出直肠和膀胱内容物溢入是主要挑战,限制其临床适用性。

要点

  • 11例直肠腺癌患者中5例良好反应、6例不良反应,除灌注外其他PET参数变化与结局无明确趋势。
  • 4小时静态PET示中位肿瘤-肌肉SUVmax从基线2.14降至第2周1.30,中位肿瘤-血液SUVmax从2.46降至1.61。
  • 作者强调直肠和膀胱内容物溢入是[18F]FMISO PET判读的主要问题,应减少膀胱溢入以提高数据质量。

核心结论

  • 该小样本试点研究显示直肠癌[18F]FMISO PET扫描在实施和判读上存在显著挑战,主要问题为直肠和膀胱内容物的非肿瘤示踪剂溢入。
  • 作者认为应着重减少膀胱溢入效应以提高数据质量,并指出该初步研究显示判读的根本困难限制了其临床适用性。

研究设计与样本

  • 经活检证实的直肠腺癌患者,在基线和放化疗8-10次分割后(第2周)行[18F]FMISO PET扫描,采集0-45分钟、2小时和4小时图像。
  • 前6例患者未接受灌肠(非灌肠组),后4例患者在PET-CT扫描前接受灌肠(灌肠组);[18F]FMISO生产失败2次。
  • 4小时静态PET图像采用肿瘤-肌肉SUVmax和肿瘤-血液SUVmax分析;0-45分钟动态PET扫描采用Casciari模型报告缺氧和灌注;使用Akaike信息准则比较不同药代动力学模型的数据拟合。
  • 病理肿瘤退缩分级采用美国癌症联合委员会(AJCC)7.0版评分;使用Shapiro-Wilk检验评估数据正态性。

主要发现

  • 11例患者中5例(5/11)为良好反应者(AJCC 0/1或良好临床反应),6例(6/11)为不良反应者(AJCC 2/3或不良临床反应)。
  • 肿瘤-肌肉SUVmax中位数基线为2.14(IQR 0.58),第2周为1.30(IQR 0.19);相应中位肿瘤缺氧体积基线为1.08(IQR 1.31)cm3,第2周为0(IQR 0.15)cm3。
  • 肿瘤-血液SUVmax中位数基线为2.46(IQR 1.50),第2周为1.61(IQR 0.14);相应中位肿瘤缺氧体积基线为5.68(IQR 5.86)cm3,第2周为0.76(IQR 0.78)cm3。
  • 0-45分钟肿瘤建模中,中位缺氧基线为0.92(IQR 0.41)min-1,第2周为0.70(IQR 0.10)min-1;中位灌注基线为4.10(IQR 1.71)ml g-1 min-1,第2周为2.48(IQR 3.62)ml g-1 min-1。
  • 在9/11例有两次PET扫描的患者中,不良反应者肿瘤灌注下降、反应者升高,但有一例患者例外;其他PET参数变化与临床结局均未见明确趋势。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论指出该初步研究显示直肠癌[18F]FMISO PET判读存在根本困难,限制了其临床适用性。

局限性

  • 作者自述为小样本数据集的试点研究。
  • 作者指出[18F]FMISO PET扫描直肠癌在实施和判读上存在显著挑战,主要问题为直肠和膀胱内容物非肿瘤示踪剂溢入。
  • 作者指出该初步研究显示判读的根本困难限制了其临床适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an increasing interest in developing predictive biomarkers of tissue hypoxia using functional imaging for personalised radiotherapy in patients with rectal cancer that are considered for neoadjuvant chemoradiotherapy (CRT). The study explores [18F]fluoromisonidazole ([18F]FMISO) positron emission tomography (PET) scans for predicting clinical response in rectal cancer patients receiving neoadjuvant CRT. METHODS: Patients with biopsy-proven rectal adenocarcinoma were imaged at 0-45 min, 2 and 4 h, at baseline and after 8-10 fractions of CRT (week 2). The first 6 patients did not receive an enema (the non-enema group) and the last 4 patients received an enema before PET-CT scan (the enema group). [18F]FMISO production failed on 2 occasions. Static PET images at 4 h were analysed using tumour-to-muscle (T:M) SUVmax and tumour-to-blood (T:B) SUVmax. The 0-45 min dynamic PET scans were analysed using Casciari model to report hypoxia and perfusion. Akaike information criteria (AIC) were used to compare data fittings for different pharmacokinetic models. Pathological tumour regression grade was scored using American Joint Committee on Cancer (AJCC) 7.0. Shapiro-Wilk test was used to evaluate the normality of the data. RESULTS: Five out of eleven (5/11) patients were classed as good responders (AJCC 0/1 or good clinical response) and 6/11 as poor responders (AJCC 2/3 or poor clinical response). The median T:M SUVmax was 2.14 (IQR 0.58) at baseline and 1.30 (IQR 0.19) at week 2, and the corresponding median tumour hypoxia volume was 1.08 (IQR 1.31) cm3 and 0 (IQR 0.15) cm3, respectively. The median T:B SUVmax was 2.46 (IQR 1.50) at baseline and 1.61 (IQR 0.14) at week 2, and the corresponding median tumour hypoxia volume was 5.68 (IQR 5.86) cm3 and 0.76 (IQR 0.78) cm3, respectively. For 0-45 min tumour modelling, the median hypoxia was 0.92 (IQR 0.41) min-1 at baseline and 0.70 (IQR 0.10) min-1 at week 2. The median perfusion was 4.10 (IQR 1.71) ml g-1 min-1 at baseline and 2.48 (IQR 3.62) ml g-1 min-1 at week 2. In 9/11 patients with both PET scans, tumour perfusion decreased in non-responders and increased in responders except in one patient. None of the changes in other PET parameters showed any clear trend with clinical outcome. CONCLUSIONS: This pilot study with small number of datasets revealed significant challenges in delivery and interpretation of [18F]FMISO PET scans of rectal cancer. There are two principal problems namely spill-in from non-tumour tracer activity from rectal and bladder contents. Emphasis should be made on reducing spill-in effects from the bladder to improve data quality. This preliminary study has shown fundamental difficulties in the interpretation of [18F]FMISO PET scans for rectal cancer, limiting its clinical applicability.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Puri T, Greenhalgh TA, Wilson JM, et al. [18F]Fluoromisonidazole PET in rectal cancer. EJNMMI Res. 2017. PMID: 28933018. doi:10.1186/s13550-017-0324-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。